Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 pharmacokinetics in renal impairment
NCT06814132Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of opevesostat (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve from 0 to Infinity at 72 hours, Area Under the Concentration Versus Time Curve From 0 to the Time of the Last Quantifiable Sample at 72 hours and 6 more. Started Apr 2025; status: completed.
02
Drugs
opevesostat
Beyond the preview
Go deeper on NCT06814132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814132.